Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Licensing In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Shire addition of European rights to Dynepo is key driver of $1.6 bil. TKT merger. Roche’s Xenical to be detailed by GSK. Schering-Plough to out-license U.S. rights to Phase III quinolone antibiotic garenoxacin. Kos plans Teveten and Cardizem LA re-launch in June following purchase/licensing pact with Biovail. More licensing deals in brief

You may also be interested in...



Biotech IPO Path Often Leads Toward Pharma Partnerships – BIO Venture Forum

 

Approval In Brief

Halozyme's Hylenex is NME: Recombinant human hyaluronidase (formerly Enhanze SC) spreading agent is approved Dec. 2 as a new molecular entity via the 505(b)(2) pathway, entering an increasingly crowded hyaluronidase market. FDA is considering all hyaluronidase products to be NMEs because of the lack of characterization. Hylenex, which will be marketed by Baxter, is indicated "as an adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoclysis and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents." PrimaPharm's bovine-derived hyaluronidase Hydase was approved Oct. 25, while Amphastar's bovine-derived Amphadase and Ista's ovine-derived Vitrase were both approved in 2004. All four of the approved agents received priority reviews (Pharmaceutical Approvals Monthly November 2005, p. 14)...

Shire Submits Elaprase BLA For Hunter Syndrome

Shire's Elaprase (idursulfase) could be approved as early as May 2006 for Hunter syndrome if FDA grants the company's request for priority review of the BLA submission, announced Nov. 24

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel